Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature

BACKGROUND. Everolimus, an oral mTOR (mammalian target of rapamycin) inhibitor, is currently approved for the treatment of progressive pancreatic neuroendocrine tumors (NETs). Although promising, only scattered data, often from nondedicated studies, are available for extrapancreatic NETs. PATIENTS A...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncologist
Autori principali: Faggiano, Antongiulio, Malandrino, Pasqualino, Modica, Roberta, Agrimi, Daniela, Aversano, Maurizio, Bassi, Vincenzo, Giordano, Ernesto A., Guarnotta, Valentina, Logoluso, Francesco A., Messina, Erika, Nicastro, Vincenzo, Nuzzo, Vincenzo, Sciaraffia, Marcello, Colao, Annamaria
Natura: Artigo
Lingua:Inglês
Pubblicazione: AlphaMed Press 2016
Soggetti:
Endocrinology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4943387/
https://ncbi.nlm.nih.gov/pubmed/27053503
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0420
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi